Skip to main content
  • Nederlands
    • English
    • Français

Home
  • Inloggen
  • Therapeutische domeinen
    • Cardiologie
      • ASCVD
    • Dermatologie
      • Netelroos
    • Hematologie
      • ITP
    • Luchtwegen
    • Neurologie
      • Multiple sclerose
    • Oncologie
      • Borstkanker
      • Prostate Cancer (mCRPC)
    • Oogheelkunde
    • Reumatologie
  • Congressen en evenementen
    • Cardiologie
      • BSC
      • ESC
    • Dermatologie
      • EADV
      • Sharing is Caring
    • Hematologie
      • ASH
      • EHA
      • ESH
    • Neurologie
      • CMSC
      • EAN
      • ECTRIMS
    • Oncologie
      • ASCO
      • EBCC
      • ESMO
      • SABCS
    • Reumatologie
      • Sharing is Caring
  • Contact

Popular Search

  • improved
  • improving
  • aimovig
  • migration
  • migraine

Recent News

RLTech and Nurse Academy
Page protected by password
Netelroos - Doe the test
Search
  • Dosing

    Twitter Linkedin Facebook Pinterest Google plus
  • Patient Resources - Scemblix

    Twitter Linkedin Facebook Pinterest Google plus
  • MPN10 - Symptoomzoeker

      Download Dutch document     .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button below
  • MPN10 - Connaissez votre score

      Download French document     .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button below
  • Indication - Kesimpta

    Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features 1

    Both newly diagnosed patients and patients switching from...

    Twitter Linkedin Facebook Pinterest Google plus
  • Efficacy - Kesimpta

    Twitter Linkedin Facebook Pinterest Google plus
  • Safety Profile - Kesimpta

    Twitter Linkedin Facebook Pinterest Google plus
  • Reimbursement / E-health - Kesimpta

    Kesimpta ® is reimbursed in Belgium for adult patients with clinically proven relapsing multiple sclerosis (RMS) who meet the following criteria* :

    The patient has a fast evolving, serious form of relapsing multiple sclerosis (RMS...

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action

    Kesimpta ® is a targeted and precisely delivered B-cell therapy 1,5

    B-cells play a central role in the pathogenesis of MS 4

    KESIMPTA ® (ofatumumab) is a fully human anti...

    Twitter Linkedin Facebook Pinterest Google plus
  • Administration & Dosing

    Twitter Linkedin Facebook Pinterest Google plus
  • < vorige
page 

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
 of  14
  • volgende >

Filter by specialisme:

Volg Novartis

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sitemap
Cookie Settings
©2025 Novartis België en Luxemburg
  • Gebruiksvoorwaarden
  • Over cookies
Deze website is bestemd voor zorgverleners in België en Luxemburg